In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jiangsu Hengrui Medicine Co. Ltd.

www.hrs.com.cn

Latest From Jiangsu Hengrui Medicine Co. Ltd.

Venture Funding Deals: Sumitomo Alliance With Roivant Takes Shape

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October to November.

Deals Financing

Who's In And Who's Out In China's Largest Reimbursed Drug List Revamp?

Some manufacturers willing to offer global-low prices in exchange for reimbursement coverage in the world's second-largest pharma market.

China Reimbursement

Hello NMPA: China Approval For Astellas's Xtandi, Keytruda Set For Fourth Indication

Astellas’s Xtandi gets its latest approval in China, where Merck’s Keytruda is set for another win.

China Regulation

After US Approval, BeiGene Set To Gain Sixth PD-1 Green Light In China

Beijing-based BeiGene is set to score two big wins in a row as it pursues innovation. After securing US approval for its BTK inhibitor zanubrutinib for mantle cell lymphoma, its PD-1 inhibitor has sailed through a technical review in China.
China Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Jiangsu Hengrui Medicine Co. Ltd.
  • Senior Management
  • Piaoyang Sun, Chmn.
    Lianshan Zhang, PhD, Pres., Global R&D
  • Contact Info
  • Jiangsu Hengrui Medicine Co. Ltd.
    Phone: 800 828 3900
    Lianyung Eco & Tech Development Zone
    7 Kunlunshan Rd
    , 222000
    China
UsernamePublicRestriction

Register